MA49144A - Polythérapies pour le traitement du cancer - Google Patents
Polythérapies pour le traitement du cancerInfo
- Publication number
- MA49144A MA49144A MA049144A MA49144A MA49144A MA 49144 A MA49144 A MA 49144A MA 049144 A MA049144 A MA 049144A MA 49144 A MA49144 A MA 49144A MA 49144 A MA49144 A MA 49144A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapies
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508363P | 2017-05-18 | 2017-05-18 | |
| US201762508481P | 2017-05-19 | 2017-05-19 | |
| US201762578204P | 2017-10-27 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49144A true MA49144A (fr) | 2020-03-25 |
Family
ID=62705671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049144A MA49144A (fr) | 2017-05-18 | 2018-05-18 | Polythérapies pour le traitement du cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11622961B2 (fr) |
| EP (1) | EP3624850A1 (fr) |
| JP (1) | JP2020520921A (fr) |
| KR (1) | KR20200005662A (fr) |
| CN (1) | CN110913911A (fr) |
| AU (2) | AU2018270112A1 (fr) |
| BR (1) | BR112019024135A2 (fr) |
| CA (1) | CA3063715A1 (fr) |
| IL (1) | IL270720A (fr) |
| MA (1) | MA49144A (fr) |
| MX (1) | MX2019013755A (fr) |
| WO (1) | WO2018213732A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| CA3004152C (fr) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Formulations sous-cutanee d'anticorps anti-cd38 et leurs utilisations |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| CN111918667A (zh) * | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| ES3007236T3 (en) * | 2018-09-04 | 2025-03-19 | Pfizer | Cd47 blockade with parp inhibition for disease treatment |
| JP2022504228A (ja) | 2018-10-03 | 2022-01-13 | テサロ， インコーポレイテッド | ニラパリブ遊離塩基の結晶形態 |
| ES2986628T3 (es) * | 2019-02-13 | 2024-11-12 | Creatv Microtech Inc | Métodos basados en CCR5 para predecir la supervivencia global y libre de progresión en sujetos con cáncer |
| WO2020225753A2 (fr) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Procédés de caractérisation et méthodes de traitement d'un type de cancer à l'aide d'images de cancer |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| CA3168493A1 (fr) * | 2020-02-20 | 2021-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Utilisation de castalagine ou ses analogues permettant une efficacite anticancereuse et permettant d'accroitre la reponse aux inhibiteurs de point de controle immunitaire |
| CA3169303A1 (fr) * | 2020-02-24 | 2021-09-02 | Xiaokun SHEN | Application anti-coronavirus de l'inhibiteur de la poly adp-ribose polymerase |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| WO2022173932A1 (fr) * | 2021-02-11 | 2022-08-18 | Dana-Farber Cancer Institute, Inc. | Procédés de traitement de cancers à l'aide d'agonistes de sting |
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| JP2024517381A (ja) * | 2021-04-11 | 2024-04-22 | アダジーン インコーポレイテッド | がんを治療するための併用療法 |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| US20240390352A1 (en) * | 2021-09-23 | 2024-11-28 | New Cancer Cure - Bio Co.,Ltd. | Pharmaceutical composition for preventing or treating cancer comprising carnitine acylcarnitine carrier inhibitor and antitumor agent |
| TW202337897A (zh) * | 2021-11-18 | 2023-10-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法 |
| WO2023133409A2 (fr) * | 2022-01-04 | 2023-07-13 | Cornell University | Polythérapies comprenant des inhibiteurs de parp1 |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN116370607A (zh) * | 2023-03-20 | 2023-07-04 | 中国人民解放军陆军军医大学第一附属医院 | 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用 |
| WO2024216089A1 (fr) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Polythérapie à base d'anticorps anti-dectine-2 |
| CN118718000A (zh) * | 2023-06-19 | 2024-10-01 | 上海市第六人民医院 | 药物组合物及其在制备治疗肾癌的药物中的用途 |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| KR20250156324A (ko) * | 2024-04-25 | 2025-11-03 | 한국 한의학 연구원 | 루카파립 캄실레이트를 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| CA1329771C (fr) | 1988-09-01 | 1994-05-24 | Shoji Kishimoto | Agent inhibiteur de l'angiogenese |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2647545C (fr) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp) |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2217244A4 (fr) | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| WO2009087474A2 (fr) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonistes pour des systèmes peptidiques antimicrobiens |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| EP3255060A1 (fr) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
| CN102307475A (zh) | 2009-02-04 | 2012-01-04 | 彼帕科学公司 | 用与生长因子抑制剂组合的parp抑制剂治疗肺癌 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011153383A1 (fr) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine. |
| EP3012329B1 (fr) | 2010-06-18 | 2017-10-25 | Myriad Genetics, Inc. | Procédés et matériaux permettant d'évaluer la perte d'hétérozygosité |
| WO2012027224A1 (fr) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Méthodes de prédiction d'une réponse anticancéreuse |
| CA2742342A1 (fr) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013182645A1 (fr) | 2012-06-07 | 2013-12-12 | Institut Curie | Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines |
| EP2928473B1 (fr) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Arylation n-2 régiosélective d'indazoles |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2015086473A1 (fr) | 2013-12-09 | 2015-06-18 | Institut Curie | Procede pour la detection de l'inactivation de voie de recombinaison homologue (brca1/2) dans des tumeurs humaines |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| WO2015116868A2 (fr) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Profilage moléculaire de modulateurs immunitaires |
| WO2015184145A1 (fr) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Utilisation de l'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
| US20210322415A1 (en) | 2016-02-15 | 2021-10-21 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| WO2018129553A1 (fr) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210106574A1 (en) | 2017-12-27 | 2021-04-15 | Tesaro, Inc. | Methods of Treating Cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-05-18 KR KR1020197037232A patent/KR20200005662A/ko not_active Ceased
- 2018-05-18 US US16/614,131 patent/US11622961B2/en active Active
- 2018-05-18 AU AU2018270112A patent/AU2018270112A1/en not_active Abandoned
- 2018-05-18 CN CN201880047169.9A patent/CN110913911A/zh active Pending
- 2018-05-18 CA CA3063715A patent/CA3063715A1/fr active Pending
- 2018-05-18 MX MX2019013755A patent/MX2019013755A/es unknown
- 2018-05-18 BR BR112019024135-3A patent/BR112019024135A2/pt not_active IP Right Cessation
- 2018-05-18 JP JP2019563582A patent/JP2020520921A/ja active Pending
- 2018-05-18 WO PCT/US2018/033437 patent/WO2018213732A1/fr not_active Ceased
- 2018-05-18 MA MA049144A patent/MA49144A/fr unknown
- 2018-05-18 EP EP18733393.5A patent/EP3624850A1/fr not_active Withdrawn
-
2019
- 2019-11-17 IL IL270720A patent/IL270720A/en unknown
-
2021
- 2021-08-09 AU AU2021215113A patent/AU2021215113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210008053A1 (en) | 2021-01-14 |
| BR112019024135A2 (pt) | 2020-06-02 |
| WO2018213732A1 (fr) | 2018-11-22 |
| IL270720A (en) | 2020-01-30 |
| JP2020520921A (ja) | 2020-07-16 |
| AU2018270112A1 (en) | 2019-12-12 |
| AU2021215113A1 (en) | 2021-08-26 |
| CN110913911A (zh) | 2020-03-24 |
| US11622961B2 (en) | 2023-04-11 |
| EP3624850A1 (fr) | 2020-03-25 |
| MX2019013755A (es) | 2020-07-20 |
| KR20200005662A (ko) | 2020-01-15 |
| CA3063715A1 (fr) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| EP3494142A4 (fr) | Anticorps anti-siglec-7 pour le traitement du cancer | |
| EP3432927A4 (fr) | Inhibiteurs trispécifiques pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| EP3285773A4 (fr) | Polythérapie pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3400010A4 (fr) | Combinaisons anti-her2 pour le traitement des tumeurs | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3359192A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| EP3362066A4 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3331510A4 (fr) | Thérapies combinatoires pour le traitement du cancer | |
| EP3462883A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP3503887A4 (fr) | Combinaisons pour le traitement du cancer |